Table of contents
January 2005 Volume 2 No 1
Editorial
Viewpoint
Thermal ablation: a potential solution for managing the small renal tumor
2Empirical evidence indicates that the number of small renal lesions being identified is rising. Typically treated with nephrectomy or partial nephrectomy, Stephen Solomon shares his view on the emerging role of radiofrequency ablation and cryotherapy in the management of small renal tumors.
Research Highlights
Surgical versus medical castration in prostate cancer patients
4Prostatitis and pelvic pain: assessment of current treatments
4Female urinary incontinence: evidence of familial risk
4Salvage surgery in prostate cancer: assessment of rectal wall invasion
5Towards a treatment for low sperm motility in men with spinal cord injury
5Sexual function following prostatectomy: role for steroids?
6Small-cell carcinoma of the bladder: a retrospective study
8Minimally-invasive treatment for intrinsic sphincter deficiency
8Practice Points
For how long after flexible cystoscopy do artifactual cytological changes of urine persist?
10Do self-directed pelvic floor exercises relieve symptoms of SUI as effectively as supervised physiotherapy?
12Should the uterus and ovaries be removed, and the vagina resected, routinely during radical cystectomy?
14Does addition of 6 months' androgen suppression to radiotherapy prolong survival of men with prostate cancer?
16Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?
18Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
20Reviews
Can prostate cancer be prevented?
24Following the outcome of the Prostate Cancer Prevention Trial, and with data accruing for other agents, primary chemoprevention of prostate cancer is becoming a realistic strategy for managing cancers that are identified early. The evidence relating to the different candidate agents for chemoprevention of prostate cancer is reviewed.
doi:10.1038/ncpuro0072 | Full Text | PDF (128K)
Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies
32Despite improvements in surgical and radiotherapeutic techniques, a significant number of patients with locally advanced bladder cancer remain at a high risk of developing systemic disease. Jorge Garcia and Robert Dreicer discuss the conflicting evidence available for the use of neoadjuvant and adjuvant chemotherapy for bladder cancer.
doi:10.1038/ncpuro0068 | Full Text | PDF (106K)
Drug Insight: lycopene in the prevention and treatment of prostate cancer
38This Drug Insight examines the mechanisms behind the antioxidant lycopene, and its association with the health promoting effects attributed to the consumption of tomatoes and tomato extracts. Data on the anticancer properties of lycopene are compelling, but it is too early to attribute all the health benefits of tomatoes to this compound.
doi:10.1038/ncpuro0073 | Full Text | PDF (113K)
Technology Insight: vaccine therapy for prostate cancer
44Despite the amount of research that has gone into producing vaccines against cancer, these vaccines have yet to show clinical benefit. This article by J Vieweg and J Dannull reviews the current status of vaccination strategies for prostate cancer, and gives an update on the different stages in their development.
doi:10.1038/ncpuro0079 | Full Text | PDF (160K)
